



February 7, 2019

## **Terumo Decides Two-for-One Stock Split**

TOKYO, JAPAN – February 7, 2019 – Terumo Corporation (TSE: 4543) today announced that its Board of Directors has decided a two-for-one stock split and an increase from 1.519 billion to 3.038 billion in the number of authorized shares of the Company's common stock.

On April 1, 2019, each shareholder of record at the close on March 31, 2019 will receive one additional share of common stock for every outstanding share of common stock held.

### **About Terumo Corporation**

Tokyo-based Terumo Corporation is one of the world's leading medical device manufacturers with over \$5 billion in sales and operations in more than 160 nations. Founded in 1921, the company develops, manufactures and distributes world-class medical devices including products for use in cardiothoracic surgery, interventional procedures and transfusion medicine; the company also manufactures a broad array of syringe and hypodermic needle products for hospital and physician office use. Terumo contributes to society by providing valued products and services to the health care market and by responding to the needs of health care providers and the people they serve. Terumo Corporation's shares are listed on the first section of the Tokyo Stock Exchange (No. 4543, Reuters symbol <4543.T>, or Bloomberg 4543: JP) and is a component of the Nikkei 225, Japan's leading stock index.

### **Disclaimer**

Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts on projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition. The market share information in this press release is partly derived from our own independent research.

###